NCT04606732 CardioVascular Disease Progression and Prognosis in COVID-19
| NCT ID | NCT04606732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bologna |
| Condition | Covid19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2020-09-20 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2020-09-20 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CVP-COVID19 registry is both a retrospective and prospective study design in order to identify predictors of cardiovascular disease progression and mortality for COVID-19. The registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2 admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The study does not test any new diagnostic or therapeutic approach. Patients are treated according to good clinical practice. Patients characteristics, including medical history (with particular attention to cardiovascular and pneumological risk factors), features of physical examination, results laboratory and radiological tests and treatments (pre- and in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate and propensity) are performed in order to identify factors associated with disease progression. Primary endpoint: mortality.
Eligibility Criteria
Inclusion Criteria: hospitalization for COVID-19 Exclusion Criteria: age \<18 years
Contact & Investigator
Olivia Manfrini, MD
PRINCIPAL INVESTIGATOR
DIMEC, Università di Bologna
Frequently Asked Questions
Who can join the NCT04606732 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Covid19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04606732 currently recruiting?
Yes, NCT04606732 is actively recruiting participants. Contact the research team at olivia.manfrini@unibo.it for enrollment information.
Where is the NCT04606732 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT04606732 clinical trial?
NCT04606732 is sponsored by University of Bologna. The principal investigator is Olivia Manfrini, MD at DIMEC, Università di Bologna. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.